Syndax Pharmaceuticals, Inc. (SNDX) Balance Sheet

The erosion appears driven by sustained operating losses and accumulated deficit growth, with retained earnings moving from roughly -$1.1B to -$1.6B across the period. The shift from a positive equity base to a negative one suggests the company's balance sheet is increasingly reliant on liability-side funding rather than shareholder capital. Investors should monitor whether further capital raises can restore equity or whether the deficit deepens.

Debt was negligible through 2025Q2 and then stepped up sharply in 2025Q3 and again in 2026Q2, suggesting new borrowing tied to operating needs rather than a strategic capital structure choice. With equity negative, the D/E ratio loses interpretive value, and the debt load relative to a cash balance of $135.9M raises questions about servicing capacity. The refinancing schedule and covenant terms are not visible in the supplied data, so their risk warrants further investigation.

A high current ratio may reflect a large short-term asset base, possibly receivables or milestone-related balances, rather than readily deployable cash. The fall in cash between 2026Q2 and 2026Q3 alongside rising quarterly operating losses suggests the liquidity buffer is being consumed faster than it is replenished. Runway estimates depend on the timing of milestone receipts, which the data does not confirm.

The absence of shareholder returns is expected for a pre-commercial biotech, but the equity line has moved from a $366.4M surplus to a deficit, indicating losses are outpacing any equity issuance captured in the data. Stock-based compensation of roughly $15.3M per quarter adds a non-cash expense that partly offsets cash losses in reported earnings. Future equity issuance to fund commercialization would likely dilute existing holders, a risk the balance sheet alone cannot quantify.